Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2227376 | 0.91 | HDAC6 (1.00) | HDAC6 | |
| SCHEMBL2228828 | 0.85 | HDAC6 (1.00) | HDAC6 | |
| SCHEMBL2225339 | 0.82 | HDAC6 (1.00) | HDAC6 | |
| SCHEMBL2225891 | 0.81 | HDAC6 (1.00) | HDAC6 | |
| SCHEMBL2225436 | 0.79 | HDAC6 (1.00) | HDAC6 | |
| SCHEMBL2227727 | 0.79 | HDAC6 (1.00) | HDAC6 | |
| SCHEMBL2226947 | 0.79 | HDAC6 (1.00) | HDAC6 | |
| SCHEMBL2284673 | 0.78 | HDAC6 (1.00) | HDAC6 | |
| SCHEMBL2225175 | 0.77 | HDAC6 (1.00) | HDAC6 | |
| SCHEMBL2226167 | 0.77 | HDAC6 (1.00) | HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110300134-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2011-12-08 | — | — | US | claimed |
| WO-2011091213-A2 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2011-07-28 | — | — | WO | claimed |
| US-10648038-B2 | Biomarkers to identify patients that will respond to treatment and treating such patients | ACETYLON PHARMACEUTICALS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20200030325-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | ACETYLON PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| EP-2839037-B1 | BIOMARKERS TO IDENTIFY PATIENTS THAT WILL RESPOND TO TREATMENT AND TREATING SUCH PATIENTS | ACETYLON PHARMACEUTICALS INC (US) | 2018-12-26 | — | — | EP | disclosed |
| US-20170327895-A1 | Biomarkers To Identify Patients That Will Respond To Treatment And Treating Such Patients | ACETYLON PHARMACEUTICALS, INC. | 2017-11-16 | — | — | US | disclosed |
| US-20170305866-A1 | Histone Deacetylase 6 Selective Inhibitors for the Treatment of Bone Disease | THE GENERAL HOSPITAL CORPORATION | 2017-10-26 | — | — | US | disclosed |
| US-9663825-B2 | Biomarkers to identify patients that will respond to treatment and treating such patients | ACETYLON PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9512083-B2 | Histone deacetylase 6 selective inhibitors for the treatment of bone disease | THE GENERAL HOSPITAL CORPORATION (US) | 2016-12-06 | — | — | US | disclosed |
| EP-3091004-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | Acetylon Pharmaceuticals, Inc. (US) | 2016-11-09 | — | — | EP | disclosed |
| EP-3091004-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | Acetylon Pharmaceuticals, Inc. (US) | 2016-11-09 | — | — | EP | disclosed |
| EP-2526093-B1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS INC (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2526093-B1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS INC (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20150045380-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS | 2015-02-12 | — | — | US | disclosed |
| US-20140378385-A1 | Histone Deacetylase 6 Selective Inhibitors for the Treatment of Bone Disease | THE GENERAL HOSPITAL CORPORATION (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140142117-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS, INC. | 2014-05-22 | — | — | US | disclosed |
| WO-2013158984-A1 | BIOMARKERS TO IDENTIFY PATIENTS THAT WILL RESPOND TO TREATMENT AND TREATING SUCH PATIENTS | ACETYLON PHARMACEUTICALS, INC. (US) | 2013-10-24 | — | — | WO | disclosed |
| US-8394810-B2 | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof | ACETYLON PHARMACEUTICALS (US) | 2013-03-12 | — | — | US | disclosed |
| WO-2013013113-A2 | HISTONE DEACETYLASE 6 SELECTIVE INHIBITORS FOR THE TREATMENT OF BONE DISEASE | THE GENERAL HOSPITAL CORPORATION (US) | 2013-01-24 | — | — | WO | disclosed |
| WO-2011091213-A2 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110300134-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885 |
| US-20150045380-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885 |
| US-20140378385-A1 | Histone Deacetylase 6 Selective Inhibitors for the Treatment of Bone Disease | HDAC1, HDAC6, HDAC9 | HDAC6 2/4885 |
| US-20200030325-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885 |
| US-20170305866-A1 | Histone Deacetylase 6 Selective Inhibitors for the Treatment of Bone Disease | HDAC1, HDAC6, HDAC9 | HDAC6 2/4885 |
| US-20140142117-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.